Compare EVAX & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVAX | HIND |
|---|---|---|
| Founded | 2008 | N/A |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.7M | 28.0M |
| IPO Year | 2021 | 2016 |
| Metric | EVAX | HIND |
|---|---|---|
| Price | $3.98 | $3.26 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $12.33 | N/A |
| AVG Volume (30 Days) | ★ 68.2K | N/A |
| Earning Date | 11-06-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,650,000.00 | N/A |
| Revenue This Year | $128.77 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 132.17 | N/A |
| 52 Week Low | $1.20 | N/A |
| 52 Week High | $12.15 | N/A |
| Indicator | EVAX | HIND |
|---|---|---|
| Relative Strength Index (RSI) | 34.64 | 44.57 |
| Support Level | $3.88 | $3.00 |
| Resistance Level | $4.85 | $3.25 |
| Average True Range (ATR) | 0.36 | 0.34 |
| MACD | -0.09 | 0.07 |
| Stochastic Oscillator | 8.13 | 47.18 |
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.
Vyome Holdings Inc is a reseach and development company. The Company operates in two segments, biotechnology and pharmaceutical products. The biotechnology segment comprises of operations around VT-1953, VT-1908, and VB-1953 programs that are in development, and the pharmaceutical segment comprises of antifungal products manufacturing and distribution.